Vir Biotechnology shares with SoftBank in the beginning of a market


(Reuters) – Vir SoftBank-supported Biotechnology Shares (VIR.O) It fell by as much as 28% in one of the worst start times in the market in recent months, adding to the gloom in the IPO market after WeWork failed to try to list its stock.

Vir deals with another disaster with Japanese SoftBank (9984.T), which is a major influence on the first public convincing offer of WeWork last month after investor doubts about the office's start-up pathway to profitability.

SoftBank's9984.T) The Video Fund owns $ 100-billion 19.8% of Vir after the tender, a slight decrease from 21.2% on its pre-IPO share. (

Investors and experts who have recently traced the IPO believe that companies thinking of going into public in the next 12-18 months would be very wary of the recent background against loss-making firms.

Vir provided revenue of $ 10.7 million for 2018, jumping almost four times a year earlier, but 66% of losses and approximately $ 116 million in the same period.

The researcher's shares of San Francisco's construction-based diseases opened at $ 16.15 after his initial public offer was priced at a low end to $ 20 to $ 22 per range of share price. He raised $ 142.9 million from the offer.

At the low day of $ 14.17, the company was valued at just over $ 1.5 billion.

Vir researches new therapies for infectious diseases such as hepatitis, tuberculosis and HIV, and advises some of the most high profile investors in the industry among its supporters.

Robert Nelsen, co-founded by Arch Venture Partners', SoftBank Vision Fund and the Bill & Melinda Gates Foundation are both among their greatest supporters. Biogen Inc.'s ( tBIIB.O) Is former CEO of George Scangos a CEO.

JP Morgan, Goldman Sachs, Cowen and Barclays are among the main underwriters for Vir's IPO.

Reporting by C Nivedita and Abhishek Manikandan in Bengaluru; Edited by Shailesh Kuber and Anil D Silva

Our Standards:The principles of Thomson Reuters Trust.

(tTTTranslate) US (t) VIR (t) BIOTECH (t) Germany (t) Germany (t) Japan (t) Western Europe (t) Initial Public Tenders (t) Equity Funding (t) Corporate Debt (t) ) Asia / Pacific (t) Equity Markets (t) Markets (t) United States (t) Forecasts / Warnings (t) Company Results (t) Accelerated Shares / Green Stocks (t) Biotechnology and Medical Research (TRBC) (t) Technology (TRBC) (t) Europe (t) Real Estate (T) Healthcare Markets (TBC) (t) Private Equity Funds


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.